A Study to Evaluate Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease


About this study

The purpose of this study is to investigate how abrupt loss of ovarian hormones following bilateral oophorectomy affects overall aging, physical performance, and cognitive function, including the risk for Alzheimer’s disease in women who had this procedure performed prior to natural menopause for benign conditions.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Women will be eligible for the study if they were identified and passively followed in MOA-2.
  • Women who are currently aged 55 years and older.
  • Whomen who are more than six months post chemotherapy or major surgery requiring general anesthesia.
  • Women who are willing and able to sign the informed consent.
  • To participate in the neuroimaging subset, women must be aged 60 and older.

Exclusion Criteria:

  • Women will not be eligible for this study if they are not able to read and speak English.
  • Women who are in hospice.
  • Women who are claustrophobic.
  • Women who have an implanted foreign metal object will be excluded from neuroimaging.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kejal Kantarci, M.D.

Closed for enrollment

Contact information:

Sarah Jeno



More information


Publications are currently not available

Mayo Clinic Footer